Investment analysts at StockNews.com began coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the stock. JNCE has been the topic of a number of other reports. Piper Sandler lowered shares of Jounce Therapeutics from an […]
Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) has earned an average rating of “Hold” from the six research firms that are covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among analysts […]
StockNews.com started coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research note published on Wednesday. The brokerage issued a hold rating on the stock. Several other equities research analysts have also commented on the stock. Sumitomo Mitsui Financial Group reissued a neutral rating on shares of Jounce Therapeutics in a research […]
Should You Buy or Sell Jounce Therapeutics Stock? Get The Latest JNCE Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Piper Sandler cut shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) from an overweight rating to a neutral rating in a research note issued to investors on Monday, The Fly reports. A number of other brokerages also recently issued reports on JNCE. Raymond James downgraded Jounce Therapeutics from an outperform rating to a market perform […]